Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia.

Nguyen TH, Weber W, Havari E, Connors T, Bagley RG, McLaren R, Nambiar PR, Madden SL, Teicher BA, Roberts B, Kaplan J, Shankara S.

Int J Oncol. 2012 Sep;41(3):829-38. doi: 10.3892/ijo.2012.1513. Epub 2012 Jun 12.

2.

Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.

Simi L, Venturini G, Malentacchi F, Gelmini S, Andreani M, Janni A, Pastorekova S, Supuran CT, Pazzagli M, Orlando C.

Lung Cancer. 2006 Apr;52(1):59-66. Epub 2006 Feb 28.

PMID:
16513206
3.

TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition.

Jung H, Lee KP, Park SJ, Park JH, Jang YS, Choi SY, Jung JG, Jo K, Park DY, Yoon JH, Park JH, Lim DS, Hong GR, Choi C, Park YK, Lee JW, Hong HJ, Kim S, Park YW.

Oncogene. 2008 Apr 17;27(18):2635-47. Epub 2007 Oct 29.

PMID:
17968309
4.

Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.

Hamamoto J, Soejima K, Naoki K, Yasuda H, Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Arai D, Ishioka K, Ohgino K, Betsuyaku T.

Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8.

5.

Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology.

Larzabal L, Nguewa PA, Pio R, Blanco D, Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM, Calvo A.

Br J Cancer. 2011 Nov 8;105(10):1608-14. doi: 10.1038/bjc.2011.432.

6.

Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, Morse DL.

Mol Imaging Biol. 2016 Apr;18(2):219-31. doi: 10.1007/s11307-015-0885-x.

7.

Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer.

Malentacchi F, Simi L, Nannelli C, Andreani M, Janni A, Pastorekova S, Orlando C.

Lung Cancer. 2009 Jun;64(3):271-6. doi: 10.1016/j.lungcan.2008.10.001. Epub 2008 Nov 20.

PMID:
19022520
8.

An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.

Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ.

Clin Cancer Res. 2006 Mar 1;12(5):1507-14.

9.

TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer.

Chikaishi Y, Uramoto H, Koyanagi Y, Yamada S, Yano S, Tanaka F.

Anticancer Res. 2016 Jan;36(1):121-7.

PMID:
26722035
10.

TMPRSS4 regulates levels of integrin α5 in NSCLC through miR-205 activity to promote metastasis.

Larzabal L, de Aberasturi AL, Redrado M, Rueda P, Rodriguez MJ, Bodegas ME, Montuenga LM, Calvo A.

Br J Cancer. 2014 Feb 4;110(3):764-74. doi: 10.1038/bjc.2013.761. Epub 2014 Jan 16.

11.

Hypoxia biomarkers in squamous cell carcinoma of the uterine cervix.

Ellingsen C, Andersen LM, Galappathi K, Rofstad EK.

BMC Cancer. 2015 Oct 26;15:805. doi: 10.1186/s12885-015-1828-2.

12.

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.

Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J, Pouysségur J, Hofman P.

Br J Cancer. 2010 May 25;102(11):1627-35. doi: 10.1038/sj.bjc.6605690. Epub 2010 May 11.

13.

[Expression of carbonic anhydrase IX in NSCLC and its relationship with VEGF and Ki67 expression].

Zhao X, Liu X, Guo W, Li X.

Zhongguo Fei Ai Za Zhi. 2010 Sep;13(9):861-6. doi: 10.3779/j.issn.1009-3419.2010.09.05. Chinese.

14.

Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.

Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ.

J Clin Oncol. 2003 Feb 1;21(3):473-82.

PMID:
12560438
15.

Increased BCAR1 predicts poor outcomes of non-small cell lung cancer in multiple-center patients.

Deng B, Sun Z, Jason W, Yang P.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S701-8. doi: 10.1245/s10434-013-3184-2. Epub 2013 Aug 1.

16.

Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.

Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon MG, de Geus-Oei LF, van der Drift MA, van der Heijden EH, Oyen WJ, Visser EP, Span PN, Bussink J.

J Thorac Oncol. 2014 Oct;9(10):1485-93. doi: 10.1097/JTO.0000000000000286.

17.

Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice.

Ye J, Ren Z, Gu Q, Wang L, Wang J.

DNA Cell Biol. 2011 Dec;30(12):987-94. doi: 10.1089/dna.2010.1196. Epub 2011 Jun 11.

18.

Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC, Harris AL, Sage EH.

Cancer Res. 2003 Sep 1;63(17):5376-80.

19.

Differential expression of RON in small and non-small cell lung cancers.

Kanteti R, Krishnaswamy S, Catenacci D, Tan YH, EL-Hashani E, Cervantes G, Husain AN, Tretiakova M, Vokes EE, Huet H, Salgia R.

Genes Chromosomes Cancer. 2012 Sep;51(9):841-51. doi: 10.1002/gcc.21968. Epub 2012 May 14.

PMID:
22585712
20.

Carbonic anhydrase IX in early-stage non-small cell lung cancer.

Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, Vujaskovic Z, Kelley MJ.

Clin Cancer Res. 2004 Dec 1;10(23):7925-33. Erratum in: Clin Cancer Res. 2005 Apr 1;11(7):2783.

Supplemental Content

Support Center